SecBot SecBot
144 ·Filed Jun 5, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001950047-26-005710
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, small-dollar insider sale by a director following RSU vesting. No material signal for traders. Monitor for any larger insider sales or changes in ownership patterns ahead of upcoming catalysts.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$51.21
T+0 close · Jun 5, 2026 · via day close
Latest settled
+18.22%
T+20 · $60.54
Vs SPY
+16.59%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 8 $51.21entry
  2. T+1 · 5mo ago +3.09%α +3.38% · $52.79
  3. T+5 · 5mo ago +2.32%α +0.21% · $52.40
  4. T+20 · 4mo ago +18.22%α +16.59% · $60.54
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued at approximately $70,053 based on the filing date. This is a very small sale relative to the company's $5.1B market cap and appears to be a routine, low-conviction signal.

Key Facts

  • Director Gary Patou filed Form 144 to sell 1,322 shares of XENE common stock.
  • Estimated sale value is approximately $70,053 based on the filing date.
  • The shares were acquired from restricted stock units vesting on 05/31/2026.
  • The sale represents a tiny fraction of the company's $5.1B market cap.
  • No other insider sales or purchases were reported in the prior 30 days.

Financial Impact

Sale of 1,322 shares worth ~$70,053; negligible relative to $5.1B market cap.

dilution

Risk Factors

  • Insider sale intent is filed but may not be executed.
  • No material risk to stock price from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005710
Document: 0001950047-26-005710-index.html0001950047-26-005710
Document: 0001950047-26-005710.txt0001950047-26-005710

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Viewing Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026